IADR Abstract Archives
Lipid-Lowering Agents, Endothelial Function, and Inflammation in Type 2 Diabetes
Objectives: We assessed the association between Lipid-lowering agents (LLA) use on reducing oral (gingival crevicular fluid: GCF) and/or systemic (serum) levels of markers of endothelial function or inflammation and bone related factors.
Methods:
This cross-sectional study included 248 residents of Puerto Rico with T2D, aged 40–65 years. Duration of LLA use was categorized as < 1 year; 1-4 years, and > 4 years. Serum inflammatory levels (IL-1b, TNF-α), soluble endothelial adhesion molecules (sICAM-1, sVCAM-1), and bone related factor RANKL, were examined by multiplex Luminex immunoassay and ELISA. A subset of 166 GCF samples was used to measure the GCF levels of these biomarkers and OPG using multiplex Meso Scale Discovery immunoassay. Generalized linear models (robust) were fitted to the square-root transformation of continuous forms of serum or GCF biomarkers while controlling for age, gender, education, smoking status, alcohol consumption, BMI, anti-inflammatory medication use, and LDL-cholesterol level (mg/dL).
Results:
55.8% of participants took LLA < 1 year, 17.9% for 1-4 yrs., and 26.3% > 4 yrs. LLA use for 1-4 yrs. or LLA use > 4 yrs. was associated with decrease in serum sVCAM-1 [LLA 1-4 yrs.: β= - 50.4;95% CI (-100.7; - 0.08); LLA use > 4 yrs.: β= - 65.12 (-118.43; -11.81)]. No difference was found with other serum biomarkers. LLA for 1-4 yrs. was associated with a decrease in GCF sICAM-1 [β=-4.22 (-7.73; -0.72)] and sVCAM-1 [β =-1.61(-2.77; -0.45)], and increase in RANKL/OPG [β=0.38 (0.02;0.74)] compared to LLA use < 1 year. LLA use > 4 yrs. was not associated with GCF biomarkers.
Conclusions:
Our findings suggest that LLA use is associated with a decrease in GCF and serum sICAM-1 and sVCAM-1 and an increase in GCF inflammatory and bone-related factors in individuals with T2D.
Methods:
This cross-sectional study included 248 residents of Puerto Rico with T2D, aged 40–65 years. Duration of LLA use was categorized as < 1 year; 1-4 years, and > 4 years. Serum inflammatory levels (IL-1b, TNF-α), soluble endothelial adhesion molecules (sICAM-1, sVCAM-1), and bone related factor RANKL, were examined by multiplex Luminex immunoassay and ELISA. A subset of 166 GCF samples was used to measure the GCF levels of these biomarkers and OPG using multiplex Meso Scale Discovery immunoassay. Generalized linear models (robust) were fitted to the square-root transformation of continuous forms of serum or GCF biomarkers while controlling for age, gender, education, smoking status, alcohol consumption, BMI, anti-inflammatory medication use, and LDL-cholesterol level (mg/dL).
Results:
55.8% of participants took LLA < 1 year, 17.9% for 1-4 yrs., and 26.3% > 4 yrs. LLA use for 1-4 yrs. or LLA use > 4 yrs. was associated with decrease in serum sVCAM-1 [LLA 1-4 yrs.: β= - 50.4;95% CI (-100.7; - 0.08); LLA use > 4 yrs.: β= - 65.12 (-118.43; -11.81)]. No difference was found with other serum biomarkers. LLA for 1-4 yrs. was associated with a decrease in GCF sICAM-1 [β=-4.22 (-7.73; -0.72)] and sVCAM-1 [β =-1.61(-2.77; -0.45)], and increase in RANKL/OPG [β=0.38 (0.02;0.74)] compared to LLA use < 1 year. LLA use > 4 yrs. was not associated with GCF biomarkers.
Conclusions:
Our findings suggest that LLA use is associated with a decrease in GCF and serum sICAM-1 and sVCAM-1 and an increase in GCF inflammatory and bone-related factors in individuals with T2D.